Montorsi F, Guazzoni G, Rigatti P, Pozza G
Institute of Human Anatomy, University of Milan School of Medicine, Italy.
Drugs. 1995 Sep;50(3):465-79. doi: 10.2165/00003495-199550030-00005.
Pharmacological treatment of erectile dysfunction includes all therapeutic modalities based on the use of erectogenic drugs, regardless of the route of administration. Intracavernous vasoactive injection therapy is the most commonly used treatment for erectile dysfunction. Most patients respond to intracavernous injection of either single or multiple vasoactive drugs. Major adverse effects related to this treatment include priapism, corporeal pain and the formation of nodules or plaques in the corpora cavernosa. Oral administration of drugs aimed at improving erectile function has not produced results comparable with those obtained with intracavernous injection therapy. However, in patients with psychogenic or mild organic impotence, oral treatment with drugs that influence either central or peripheral pathways controlling erection may improve erectile function. Topical administration of vasoactive drugs in the form of gels, liquid solutions or plasters is another attractive alternative for the treatment of psychogenic and mild organic erectile dysfunction. Although the ideal drug for the treatment of erectile dysfunction has not yet been identified, extensive laboratory and clinical research is ongoing and successful results are expected in the near future.
勃起功能障碍的药物治疗包括基于使用勃起药物的所有治疗方式，无论给药途径如何。海绵体内血管活性药物注射疗法是治疗勃起功能障碍最常用的方法。大多数患者对单次或多次海绵体内注射血管活性药物有反应。与这种治疗相关的主要不良反应包括阴茎异常勃起、海绵体疼痛以及海绵体内结节或斑块的形成。旨在改善勃起功能的口服药物尚未产生与海绵体内注射疗法相当的效果。然而，对于患有心因性或轻度器质性阳痿的患者，口服影响控制勃起的中枢或外周途径的药物可能会改善勃起功能。以凝胶、液体溶液或膏药形式局部应用血管活性药物是治疗心因性和轻度器质性勃起功能障碍的另一种有吸引力的选择。尽管尚未确定治疗勃起功能障碍的理想药物，但广泛的实验室和临床研究正在进行，预计在不久的将来会取得成功的结果。
